Lilly, Haya Ink Potential $1B Drug Discovery Deal to Target Obesity and Metabolic Conditions

Under a multi-year agreement announced Wednesday, Eli Lilly will leverage Haya Therapeutics’ proprietary RNA-guided genome platform to identify drug targets to address the chronic conditions.